Why advanced therapy medicinal products struggle in clinical translation: an in-depth analysis of developmental challenges in the EU - Report - MDSpire
Advertisement
Why advanced therapy medicinal products struggle in clinical translation: an in-depth analysis of developmental challenges in the EU
Clinical Report: Challenges in Clinical Translation of Advanced Therapy Medicinal Products
Overview
This report examines the complexities faced by developers of Advanced Therapy Medicinal Products (ATMPs) in the EU, highlighting key challenges in clinical trial initiation. The study identifies four main areas of concern: preclinical evidence, cell sourcing, clinical trials, and regulatory landscape.
Background
Advanced Therapy Medicinal Products (ATMPs) provide potential treatments for conditions with limited options, yet their clinical translation is fraught with challenges. Despite a regulatory framework established in the EU, access to ATMPs remains limited, with only a small number achieving marketing authorization. Understanding the hurdles in ATMP development is crucial for improving patient access to these innovative therapies.
Data Highlights
No numerical data or trial data provided in the source material.
Key Findings
Key challenges in ATMP development exist in preclinical evidence, cell sourcing, clinical trials, and regulatory landscape.
Only 29 ATMPs have received marketing authorization in the EU since the regulation's introduction in 2008.
Many ATMPs target small populations, limiting commercial incentives for large pharmaceutical companies.
Early engagement with regulators is essential for aligning developer efforts with regulatory expectations.
Practical recommendations are identified to support more efficient and harmonized clinical translation of ATMPs.
Clinical Implications
Developers of ATMPs should prioritize early engagement with regulatory bodies to navigate the complex landscape of clinical trial initiation. Understanding the specific challenges in each development phase can facilitate smoother transitions from preclinical to clinical applications.
Conclusion
The study highlights significant barriers in the clinical translation of ATMPs, emphasizing the need for improved regulatory awareness and support for developers. Addressing these challenges is vital for enhancing patient access to innovative therapies.
AI tools such as Scopus AI can aid APP researchers and clinicians to streamline specific aspects such as the initial tasks and literature search steps of the systematic review development process.
